EMA grants accelerated assessment for trastuzumab deruxtecan in metastatic breast cancer

The EMA has validated and granted accelerated assessment for trastuzumab deruxtecan to treat HER2 positive metastatic breast cancer. (Credit: Frauke Feind from Pixabay)